Zymeworks Common Stock Stock Analysis
ZYME Stock | USD 14.50 0.41 2.91% |
Zymeworks Common Stock is fairly valued with Real Value of 14.27 and Target Price of 13.97. The main objective of Zymeworks Common stock analysis is to determine its intrinsic value, which is an estimate of what Zymeworks Common Stock is worth, separate from its market price. There are two main types of Zymeworks Common's stock analysis: fundamental analysis and technical analysis.
The Zymeworks Common stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Zymeworks Common's ongoing operational relationships across important fundamental and technical indicators.
Zymeworks |
Zymeworks Stock Analysis Notes
About 99.0% of the company outstanding shares are owned by institutional investors. The book value of Zymeworks Common was at this time reported as 5.27. The company recorded a loss per share of 1.49. Zymeworks Common Stock had not issued any dividends in recent years. Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. Zymeworks Inc. was incorporated in 2003 and is headquartered in Vancouver, Canada. Zymeworks operates under Biotechnology classification in the United States and is traded on New York Stock Exchange. It employs 284 people. For more information please call Kenneth Galbraith at 302 274 8744 or visit https://www.zymeworks.com.Zymeworks Common Quarterly Total Revenue |
|
Zymeworks Common Stock Investment Alerts
Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Zymeworks Common's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Zymeworks Common Stock or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
The company reported the previous year's revenue of 76.01 M. Net Loss for the year was (118.67 M) with profit before overhead, payroll, taxes, and interest of 203.78 M. | |
Zymeworks Common Stock currently holds about 241.83 M in cash with (118.3 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.18. | |
Zymeworks Common has a poor financial position based on the latest SEC disclosures | |
Over 99.0% of the company outstanding shares are owned by institutional investors | |
Latest headline from finance.yahoo.com: Personalized Medicines Market to Surpass Valuation of USD 1352.81 Billion by 2031 SkyQuest Technology |
Zymeworks Common Stock Upcoming and Recent Events
5th of March 2024 Upcoming Quarterly Report | View | |
13th of May 2024 Next Financial Report | View | |
31st of December 2023 Next Fiscal Quarter End | View | |
5th of March 2024 Next Fiscal Year End | View | |
30th of September 2023 Last Quarter Report | View | |
31st of December 2022 Last Financial Announcement | View |
Zymeworks Largest EPS Surprises
Earnings surprises can significantly impact Zymeworks Common's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
---|---|---|---|---|---|---|---|
2024-08-01 | 2024-06-30 | -0.32 | -0.27 | 0.05 | 15 | ||
2023-11-07 | 2023-09-30 | -0.47 | -0.41 | 0.06 | 12 | ||
2018-11-06 | 2018-09-30 | -0.67 | -0.59 | 0.08 | 11 |
Zymeworks Common Environmental, Social, and Governance (ESG) Scores
Zymeworks Common's ESG score is a quantitative measure that evaluates Zymeworks Common's performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of Zymeworks Common's operations that may have significant financial implications and affect Zymeworks Common's stock price as well as guide investors towards more socially responsible investments.
Zymeworks Stock Institutional Investors
Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares | Farallon Capital Management, L.l.c. | 2024-09-30 | 1.4 M | State Street Corp | 2024-09-30 | 1.2 M | Nextech Invest Ag | 2024-09-30 | 1.1 M | Tang Capital Management Llc | 2024-09-30 | 1.1 M | Samsara Biocapital, Llc | 2024-09-30 | 1000 K | Prosight Management, Lp | 2024-09-30 | 917.6 K | Dimensional Fund Advisors, Inc. | 2024-09-30 | 849.5 K | Bridgeway Capital Management, Llc | 2024-09-30 | 742.6 K | Geode Capital Management, Llc | 2024-09-30 | 713.9 K | Ecor1 Capital, Llc | 2024-09-30 | 13.4 M | Morgan Stanley - Brokerage Accounts | 2024-09-30 | 5.1 M |
Zymeworks Market Capitalization
The company currently falls under 'Small-Cap' category with a current market capitalization of 998.72 M.Zymeworks Profitablity
The company has Profit Margin (PM) of (1.83) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (2.14) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $2.14.Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (0.22) | (0.23) | |
Return On Capital Employed | (0.26) | (0.28) | |
Return On Assets | (0.20) | (0.21) | |
Return On Equity | (0.26) | (0.27) |
Management Efficiency
Zymeworks Common Stock has return on total asset (ROA) of (0.1469) % which means that it has lost $0.1469 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2873) %, meaning that it created substantial loss on money invested by shareholders. Zymeworks Common's management efficiency ratios could be used to measure how well Zymeworks Common manages its routine affairs as well as how well it operates its assets and liabilities. As of December 3, 2024, Return On Tangible Assets is expected to decline to -0.23. In addition to that, Return On Capital Employed is expected to decline to -0.28. At present, Zymeworks Common's Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Intangibles To Total Assets is expected to grow to 0.12, whereas Non Currrent Assets Other are forecasted to decline to about 5.3 M.Last Reported | Projected for Next Year | ||
Book Value Per Share | 6.75 | 3.90 | |
Tangible Book Value Per Share | 6.21 | 3.29 | |
Enterprise Value Over EBITDA | (4.50) | (4.72) | |
Price Book Value Ratio | 1.54 | 1.46 | |
Enterprise Value Multiple | (4.50) | (4.72) | |
Price Fair Value | 1.54 | 1.46 | |
Enterprise Value | 584.7 M | 673.9 M |
Zymeworks Common Stock has shown resilience through effective management strategies. Our analysis examines how these strategies influence financial outcomes and investor returns which helps in understanding the stock's long-term potential.
Operating Margin (2.14) | Profit Margin (1.83) | Beta 1.157 | Return On Assets (0.15) | Return On Equity (0.29) |
Technical Drivers
As of the 3rd of December, Zymeworks Common maintains the Mean Deviation of 2.02, market risk adjusted performance of 0.4265, and Downside Deviation of 2.41. Relative to fundamental indicators, the technical analysis model lets you check existing technical drivers of Zymeworks Common Stock, as well as the relationship between them. Please check out Zymeworks Common Stock variance, value at risk, as well as the relationship between the Value At Risk and skewness to decide if Zymeworks Common Stock is priced fairly, providing market reflects its latest price of 14.5 per share. Given that Zymeworks Common Stock has jensen alpha of 0.2561, we strongly advise you to confirm Zymeworks Common Stock's prevalent market performance to make sure the company can sustain itself at a future point.Zymeworks Common Stock Price Movement Analysis
The output start index for this execution was twenty-seven with a total number of output elements of thirty-four. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Zymeworks Common middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Zymeworks Common Stock. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Zymeworks Common Stock Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Zymeworks Common insiders, such as employees or executives, is commonly permitted as long as it does not rely on Zymeworks Common's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Zymeworks Common insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Zymeworks Common Outstanding Bonds
Zymeworks Common issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Zymeworks Common Stock uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Zymeworks bonds can be classified according to their maturity, which is the date when Zymeworks Common Stock has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Dana 575 percent Corp BondUS235822AB96 | View | |
Boeing Co 2196 Corp BondUS097023DG73 | View | |
BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
AerCap Global Aviation Corp BondUS00773HAA59 | View |
Zymeworks Common Predictive Daily Indicators
Zymeworks Common intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Zymeworks Common stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Zymeworks Common Corporate Filings
8K | 21st of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
13A | 13th of November 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
8K | 31st of October 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
29th of October 2024 Other Reports | ViewVerify | |
8K | 18th of October 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
8K | 3rd of September 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
2nd of August 2024 Other Reports | ViewVerify |
Zymeworks Common Forecast Models
Zymeworks Common's time-series forecasting models are one of many Zymeworks Common's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Zymeworks Common's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Zymeworks Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Zymeworks Common prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Zymeworks shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Zymeworks Common. By using and applying Zymeworks Stock analysis, traders can create a robust methodology for identifying Zymeworks entry and exit points for their positions.
Last Reported | Projected for Next Year | ||
Pretax Profit Margin | (1.57) | (1.65) | |
Operating Profit Margin | (1.82) | (1.91) | |
Net Loss | (1.56) | (1.64) | |
Gross Profit Margin | (0.88) | (0.93) |
Current Zymeworks Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Zymeworks analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Zymeworks analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target Price | Advice | # of Analysts | |
13.97 | Strong Buy | 9 | Odds |
Most Zymeworks analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Zymeworks stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Zymeworks Common Stock, talking to its executives and customers, or listening to Zymeworks conference calls.
Zymeworks Stock Analysis Indicators
Zymeworks Common Stock stock analysis indicators help investors evaluate how Zymeworks Common stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Zymeworks Common shares will generate the highest return on investment. By understating and applying Zymeworks Common stock analysis, traders can identify Zymeworks Common position entry and exit signals to maximize returns.
Begin Period Cash Flow | 400.9 M | |
Common Stock Shares Outstanding | 68.9 M | |
Total Stockholder Equity | 464.8 M | |
Tax Provision | -568 K | |
Property Plant And Equipment Net | 37.5 M | |
Cash And Short Term Investments | 374.3 M | |
Cash | 157.6 M | |
Accounts Payable | 6.2 M | |
Net Debt | -130.8 M | |
50 Day M A | 13.8711 | |
Total Current Liabilities | 55.8 M | |
Other Operating Expenses | 214.1 M | |
Non Current Assets Total | 168 M | |
Non Currrent Assets Other | 7.3 M | |
Stock Based Compensation | 8.1 M |
Complementary Tools for Zymeworks Stock analysis
When running Zymeworks Common's price analysis, check to measure Zymeworks Common's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Zymeworks Common is operating at the current time. Most of Zymeworks Common's value examination focuses on studying past and present price action to predict the probability of Zymeworks Common's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Zymeworks Common's price. Additionally, you may evaluate how the addition of Zymeworks Common to your portfolios can decrease your overall portfolio volatility.
Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
Money Managers Screen money managers from public funds and ETFs managed around the world | |
Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
Global Correlations Find global opportunities by holding instruments from different markets |